Boehringer Ingelheim

This study is testing an oral medication called nerandomilast in children and adolescents aged 2 to 17 who have fibrosing interstitial lung disease, a condition that causes scarring in the lungs. The main goals are to see how the body processes the drug, check its safety, and gat…

This study is testing whether an experimental pill called BI 764198 can help people with certain kidney diseases that cause protein to leak into the urine. About 132 adults and some teenagers will take either the real pill or a placebo (sugar pill) once a day for 20 weeks, while …

This study aims to see how well the medication Jardiance works and how safe it is for people in China with a common type of heart failure (HFpEF) in real-world hospital settings. It will follow 3,000 adult patients who are newly starting Jardiance to track their health outcomes. …

This large, late-stage study is testing whether a new oral medication called nerandomilast can help control systemic sclerosis (scleroderma), a rare autoimmune disease that causes skin thickening and can damage internal organs. About 448 adults with early-stage scleroderma will b…

This study aims to see how well the drug Jardiance works compared to other standard heart failure medications in real-world Chinese patients. It will follow 5,000 adults with a weakened heart to see which treatment is better at preventing hospital stays for heart failure or death…

This study is testing whether a new targeted pill called zongertinib is safe and tolerable when combined with standard chemotherapy, with or without an immunotherapy drug (pembrolizumab), for people with advanced lung cancer that has a specific HER2 mutation. The main goal is to …

This early-stage study is testing a new cancer drug called BI 3923948 for the first time in people. It aims to find the highest safe dose when given alone or combined with an immunotherapy drug. The trial is for adults with advanced solid tumors that have spread and are accessibl…

This study aims to monitor the safety and effectiveness of spesolimab, an intravenous medication, in Korean patients experiencing severe flares of generalized pustular psoriasis. Researchers will observe 21 patients in routine medical practice to track side effects and how well t…

This study is testing whether adding a new medicine called obrixtamig to standard treatment helps people with advanced small cell lung cancer live longer. About 670 adults who haven't had treatment for this advanced stage will be randomly assigned to receive either the standard t…

This early-stage study aims to find a safe dose of a new drug, BI 1831169, when given with an existing immunotherapy (an anti-PD1 antibody) to Japanese adults with advanced solid tumors that have spread. The goal is to see how much of the new drug people can tolerate and to check…

This study is testing a new oral medication called BI 3000202 to see if it can help control disease activity in adults with moderate to severe systemic lupus erythematosus (SLE). About 405 participants will be randomly assigned to receive one of four different doses of the drug o…

This is the first study in people testing a new drug called BI 3810944 for adults with advanced solid tumors or melanoma that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug helps shrink tumors. Participants will receive the d…

This early-stage study aims to understand how a new medicine, BI 3000202, is processed by the body in people with and without liver problems. It will enroll 44 adults, including healthy volunteers and people with varying degrees of liver impairment. Each participant takes a singl…

This is an early-stage study to check the safety and how the body processes a new drug called BI 3814916. It involves 136 healthy volunteers who will receive either the drug or a placebo. The main goal is to see how well people tolerate it and to measure the drug levels in their …